/

Società

Je

Non verificato

Jeito Capital

Di cosa scriviamo

Annunci EconomiciBiotecnologiaFarmaceuticaFinanzaPubblicità/Marketing/Media/Comunicazione

14 comunicati stampa

Guarda tutti i comunicati

05/05/2026

Mercato del lavoro

Industria

Scienza

Risorse Umane

Finanza

Associazioni/Professionisti

Biotecnologia

Salute

Farmaceutica

Jeito Capital Bolsters Its Leadership Team With the Appointment of Elaine Caughey, MBA, as Partner, Business Development and Investor Relations, and Sarah Shackelton, MPA, as Partner, Talent

Fonte

Emittente

1.00

0

14/04/2026

Biotecnologia

Farmaceutica

Salute

Oncologia

Jeito Capital leads oversubscribed $75 million Series C in Adcendo ApS to Advance its First- and Best-in-class Clinical ADC1 Pipeline in Oncology

Fonte

Emittente

1.00

0

08/04/2026

Cardiologia

Biotecnologia

Farmaceutica

Oncologia

Salute

Organizzazione Aziendale

Associazioni/Professionisti

Jeito Capital Hits Record $1.2 Billion (€1 Billion)1 Close for Jeito II Fund to Drive Breakthrough Therapeutic Innovation for Patients

Fonte

Emittente

1.00

0

24/02/2026

Finanza

Annunci Economici

Pubblicità/Marketing/Media/Comunicazione

Jeito Capital Makes Significant Investment in the Second Closing of Alveus Therapeutics’ Oversubscribed Series A, Bringing Total Financing to $197 Million

Fonte

Emittente

1.00

0

15/10/2025

Finanza

Pubblicità/Marketing/Media/Comunicazione

Annunci Economici

Jeito Capital promotes Ksenija Pavletic to General Partner

Fonte

Emittente

1.00

0

10/09/2025

Finanza

Annunci Economici

Jeito Capital announces significant participation in oversubscribed $213M Series D financing for Odyssey Therapeutics to advance clinical pipeline addressing autoimmune diseases with high unmet needs

Fonte

Emittente

1.00

0

20/05/2025

Finanza

Pubblicità/Marketing/Media/Comunicazione

Annunci Economici

Jeito Capital Leads a USD 65 million Financing in ReproNovo to Develop Transformational Treatments in Reproductive Medicine and Women’s Health

Fonte

Emittente

1.00

0

12/05/2025

Finanza

Pubblicità/Marketing/Media/Comunicazione

Annunci Economici

Jeito Capital leads EUR 132 million oversubscribed Series B financing in Azafaros to advance Phase 3 clinical programs of innovative therapies in rare inherited neuro-metabolic disorders

Fonte

Emittente

1.00

0

11/05/2025

Finanza

Annunci Economici

Jeito Capital Strengthens Leadership for Next Chapter of Growth: Mehdi Ainouche Promoted to Partner, Julien Elric to Senior Principal

Fonte

Emittente

1.00

0

23/03/2025

Finanza

Pubblicità/Marketing/Media/Comunicazione

Annunci Economici

Jeito Capital co-leads the oversubscribed €78 million financing in Augustine Therapeutics to develop novel therapies for neuromuscular, cardio-metabolic and neurodegenerative diseases

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0